Tag Archives: Pascal Soriot

Tagrisso and Other Cancer Drugs Give AstraZeneca One of Pharmaceutical Industry’s Rare Pandemic Sales Profits

In the context of several pharmaceutical companies that reported sales declines in the second quarter due to COVID-19, AstraZeneca represents a rare exception, thanks to the strong performance of its cancer drugs. In the second quarter, AZ’s oncology portfolio generated $ 2.61 billion, a 24% year-over-year increase with constant exchange …

Read More »